Cargando cotizaciones...
Previsión
| Comprar |
13 |
| Mantener |
2 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Cellectis reports quarterly loss per share of $0.26 and declining revenue
Cellectis reported earnings per share of -$0.26 for the most recent quarter, after -$0.080 in the year-ago quarter. Quarterly revenue fell to $10.4 million (-17.74% versus $12.6 million). For the full year, the company shows a loss per share of -$0.670, while annual revenue rose sharply to $73.17 million (±76.61% versus $41.43 million). » Más en finanzen.net
Cellectis beats Q4 2025 revenue and EPS forecasts, stock rises
Cellectis reported Q4 2025 EPS of -$0.19 (forecast -$0.2948) and revenue of $17.1 million (forecast $10.02 million), both well above expectations. The stock rose 2.01% in premarket trading to $3.55. Cash resources of $211 million secure the company’s financial runway into the second half of 2027. The company highlights progress on the Lasme‑Cel and Eti‑Cel programmes and the validation of internal manufacturing capacities. » Más en de.investing.com
Cellectis: arbitration panel partially terminates license agreement with Servier
An arbitration panel has partially terminated the 2019 license, development and commercialization agreement between Cellectis and Servier. The decision specifically concerns the product UCART19 V1 (also ALLO-501) and obliges Cellectis, upon request, to enter into good-faith negotiations with Allogene regarding a direct licensing arrangement. All other claims brought in the arbitration were dismissed. » Más en de.investing.com
Cellectis achieves breakthrough in non-viral gene insertion method
Cellectis and Moligo present in Nature Communications a non-viral gene insertion method for hematopoietic stem and progenitor cells (HSPCs) based on enzymatically produced circular single-stranded DNA (CssDNA). The circular ssDNA format reached insertion rates above 40% and was 3- to 5-fold more efficient than linear ssDNA; in mouse models, CssDNA-edited HSPCs showed better expansion and retention of edits than with AAV6. The collaboration aims to provide a scalable alternative to viral vectors and strengthen Cellectis' position in gene editing, while analysts see a price target of $7.50 and the company, despite strong revenue growth, is not yet profitable. » Más en de.investing.com
Cellectis reports strong phase‑1 data for leukemia therapy lasme‑cel
Cellectis released promising phase‑1 data from the BALLI‑01 study of lasme‑cel (UCART22) in relapsed/refractory B‑ALL: overall response rate 68% (manufacturing process 2), 83% at the dose recommended for phase‑2 and 100% in the phase‑2 target population. In that target group, 56% achieved complete remission (CR/CRi) and about 80% were minimal residual disease (MRD) negative; 78% of patients eligible for transplant received one. The therapy showed activity even in heavily pretreated patients and was generally well tolerated. Cellectis has initiated a registration‑enabling phase‑2 study (first patient expected Q4 2025) and is targeting a BLA submission in 2028; Q2 financials showed mixed signals with revenue above forecast but an EPS miss. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 3,76 M | 89,30 % |
| Beneficio bruto | 1,27 M | 96,13 % |
| Beneficio neto | -61,47 M | 10.537,01 % |
| EBITDA | -27,79 M | 460,63 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 71,53 M € |
Número de acciones | 72,33 M |
Máximo/mínimo de 52 semanas | 4,75 € - 0,90 € |
| Dividendos | No |
Beta | 2,91 |
Ratio P/E | -0,85 |
Ratio PEG | 0,01 |
Ratio P/B | -6,20 |
Ratio P/S | 3,12 |
Perfil de la empresa
Cellectis S.A., una empresa biotecnológica en fase clínica, desarrolla productos de inmuno-oncología basados en linfocitos T editados genéticamente que expresan receptores de antígeno quiméricos para dirigirse a las células cancerosas y erradicarlas. La empresa opera a través de dos segmentos, Terapéutica y Plantas. La compañía está desarrollando UCART19, un candidato a producto de linfocitos T alogénicos para el tratamiento de neoplasias hematológicas que expresan CD19, como la leucemia linfoblástica aguda; ALLO-501 y ALLO-501A para tratar el linfoma difuso de linfocitos B grandes recidivante/refractario y el linfoma folicular; ALLO-316 para el tratamiento del carcinoma de células renales; UCART123 para el tratamiento de la leucemia mieloide aguda; y UCART22 para tratar la leucemia linfoblástica aguda de linfocitos B. También está desarrollando UCARTCS1 y ALLO-715 para el tratamiento del mieloma múltiple. La empresa mantiene alianzas estratégicas con Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; e Iovance Biotherapeutics, así como una colaboración estratégica de investigación y desarrollo con Cytovia Therapeutics, Inc. Cellectis S.A. se fundó en 1999 y tiene su sede en París, Francia.
| Nombre | Cellectis |
| CEO | Andre Choulika |
| Sede | Paris,
if Francia |
| Sitio web | |
| Salida a bolsa | 07/02/2007 |
| Empleados | 227 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Euronext | ALCLS.PA |
Pnk | CMVLF |
Frankfurt | ZVA.F |
Düsseldorf | ZVA.DU |
London | 0WA2.L |
Paris | ALCLS.PA |
München | ZVA.MU |